patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_797042 | REC_0017201 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 9.5 | 61 | male | 1 | 24 | 5.1 | 1 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:36:02.068791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941123 | REC_0017202 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 6.5 | 61 | female | 1 | 40 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.4 | false | MSS | 2026-03-15T05:36:02.069124+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742432 | REC_0017203 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 17.7 | 71 | female | 3 | 12 | 4 | 2 | osimertinib 80 mg daily | 18.7 | true | MSI-H | 2026-03-15T05:36:02.069432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804909 | REC_0017204 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 15.7 | 63 | male | 1 | 15 | 4.5 | 4 | osimertinib 80 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:36:02.069743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300736 | REC_0017205 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 14.5 | 86 | female | 2 | 2 | 6.2 | 8 | entrectinib 600 mg daily | 8.9 | true | MSI-H | 2026-03-15T05:36:02.070030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670545 | REC_0017206 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 3.8 | 75 | male | 1 | 22 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.2 | false | MSS | 2026-03-15T05:36:02.070312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643048 | REC_0017207 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 12.9 | 64 | male | 1 | 28 | 6.6 | 7 | pembrolizumab 200 mg q3w | 10.8 | false | MSI-H | 2026-03-15T05:36:02.070614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314575 | REC_0017208 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 5.3 | 63 | female | 0 | 8 | 4.2 | 4 | alectinib 600 mg BID | 6.6 | true | MSS | 2026-03-15T05:36:02.070911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352688 | REC_0017209 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 17 | 66 | male | 0 | 7 | 4.5 | 4 | entrectinib 600 mg daily | 11.4 | true | MSS | 2026-03-15T05:36:02.071216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721066 | REC_0017210 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 7.9 | 86 | male | 2 | 10 | 5.5 | 2 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:36:02.071527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334586 | REC_0017211 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 15.8 | 72 | female | 1 | 27 | 6 | 2 | osimertinib 80 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:36:02.071846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489767 | REC_0017212 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.7 | 59 | male | 0 | 17 | 6.7 | 4 | alectinib 600 mg BID | 9.9 | false | MSS | 2026-03-15T05:36:02.072367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891306 | REC_0017213 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 22 | 7.1 | 71 | male | 3 | 19 | 5.7 | 0 | pembrolizumab 200 mg q3w | 50.3 | false | MSS | 2026-03-15T05:36:02.072922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567247 | REC_0017214 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 13 | 52 | female | 0 | 16 | 5.4 | 1 | alectinib 600 mg BID | 21.1 | false | MSS | 2026-03-15T05:36:02.073322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504727 | REC_0017215 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 6 | 72 | female | 1 | 14 | 4.2 | 7 | pembrolizumab 200 mg q3w | 6.2 | true | MSS | 2026-03-15T05:36:02.073660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858198 | REC_0017216 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8.2 | 86 | female | 3 | 42 | 6 | 3 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:36:02.074010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781720 | REC_0017217 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 20 | 12 | 60 | male | 1 | 5 | 4.8 | 0 | entrectinib 600 mg daily | 60.9 | false | MSI-H | 2026-03-15T05:36:02.074389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400478 | REC_0017218 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12.1 | 65 | female | 0 | 1 | 6.4 | 5 | sotorasib 960 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:36:02.074722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648093 | REC_0017219 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 4.5 | 61 | male | 1 | 7 | 5.6 | 1 | alectinib 600 mg BID | 16.5 | false | MSS | 2026-03-15T05:36:02.075009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996057 | REC_0017220 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 8.5 | 59 | male | 1 | 13 | 5.9 | 5 | osimertinib 80 mg daily | 8.5 | true | MSS | 2026-03-15T05:36:02.075282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677760 | REC_0017221 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 8.6 | 68 | female | 1 | 17 | 5.8 | 1 | osimertinib 80 mg daily | 18.6 | true | MSS | 2026-03-15T05:36:02.075558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255209 | REC_0017222 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 6.9 | 85 | female | 2 | 12 | 6.8 | 1 | sotorasib 960 mg daily | 23.5 | true | MSS | 2026-03-15T05:36:02.075839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312323 | REC_0017223 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 14.8 | 68 | female | 1 | 27 | 5.6 | 0 | osimertinib 80 mg daily | 7.8 | false | MSS | 2026-03-15T05:36:02.076279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692925 | REC_0017224 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 16.9 | 83 | female | 2 | 15 | 6.5 | 2 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:02.076630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698093 | REC_0017225 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.8 | 73 | female | 3 | 38 | 6.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:36:02.076929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512159 | REC_0017226 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.8 | 70 | female | 2 | 17 | 4.7 | 2 | sotorasib 960 mg daily | 27.9 | true | MSI-H | 2026-03-15T05:36:02.077364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460708 | REC_0017227 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 3.5 | 63 | male | 0 | 32 | 5.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:36:02.077678+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967510 | REC_0017228 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 5.6 | 72 | female | 1 | 63 | 4.8 | 7 | pembrolizumab 200 mg q3w | 5.2 | false | MSS | 2026-03-15T05:36:02.077999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368353 | REC_0017229 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 35 | 11.7 | 71 | female | 2 | 23 | 6 | 4 | alectinib 600 mg BID | 17.6 | false | MSS | 2026-03-15T05:36:02.078325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138565 | REC_0017230 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 6.4 | 68 | male | 1 | 10 | 4.7 | 2 | alectinib 600 mg BID | 20.9 | true | MSS | 2026-03-15T05:36:02.078637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821710 | REC_0017231 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 5.2 | 78 | female | 2 | 12 | 4 | 1 | osimertinib 80 mg daily | 10.2 | false | MSS | 2026-03-15T05:36:02.078942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728070 | REC_0017232 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 8.6 | 80 | female | 2 | 45 | 2.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.5 | false | MSS | 2026-03-15T05:36:02.079260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891214 | REC_0017233 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 12.1 | 83 | male | 0 | 13 | 7.1 | 5 | sotorasib 960 mg daily | 6.8 | true | MSI-H | 2026-03-15T05:36:02.079553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913047 | REC_0017234 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 8.5 | 52 | male | 0 | 11 | 6 | 7 | entrectinib 600 mg daily | 11.4 | true | MSS | 2026-03-15T05:36:02.079816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533961 | REC_0017235 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 19 | 14.1 | 74 | female | 1 | 17 | 5 | 0 | alectinib 600 mg BID | 33.2 | false | MSS | 2026-03-15T05:36:02.080142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111698 | REC_0017236 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 17.3 | 70 | female | 1 | 9 | 5.9 | 7 | alectinib 600 mg BID | 5.1 | false | MSI-H | 2026-03-15T05:36:02.080476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106750 | REC_0017237 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 10.5 | 64 | male | 0 | 15 | 4.8 | 2 | osimertinib 80 mg daily | 21.3 | true | MSI-H | 2026-03-15T05:36:02.080800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431497 | REC_0017238 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 7.1 | 75 | male | 0 | 13 | 5.1 | 4 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:36:02.081144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173487 | REC_0017239 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.4 | 79 | male | 3 | 18 | 4.7 | 5 | osimertinib 80 mg daily | 8.3 | false | MSS | 2026-03-15T05:36:02.081700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869315 | REC_0017240 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 9.5 | 77 | female | 2 | 30 | 3.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.3 | true | MSS | 2026-03-15T05:36:02.082145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848511 | REC_0017241 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 9.2 | 69 | female | 1 | 21 | 4.5 | 8 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:36:02.082496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371487 | REC_0017242 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 14.7 | 62 | female | 1 | 22 | 6 | 7 | osimertinib 80 mg daily | 15.1 | true | MSS | 2026-03-15T05:36:02.082825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301066 | REC_0017243 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 3 | 76 | female | 1 | 8 | 7.1 | 8 | alectinib 600 mg BID | 19.8 | true | MSS | 2026-03-15T05:36:02.083143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138222 | REC_0017244 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 6 | 64 | male | 1 | 8 | 6.9 | 3 | osimertinib 80 mg daily | 10.3 | true | MSS | 2026-03-15T05:36:02.083485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234467 | REC_0017245 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 17 | 1.5 | 73 | female | 2 | 13 | 4.9 | 1 | pembrolizumab 200 mg q3w | 13 | false | MSS | 2026-03-15T05:36:02.083806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171002 | REC_0017246 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 16.2 | 50 | male | 0 | 10 | 7 | 5 | alectinib 600 mg BID | 16.5 | true | MSS | 2026-03-15T05:36:02.084877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599770 | REC_0017247 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.4 | 64 | male | 1 | 22 | 5.8 | 8 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:36:02.085485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108689 | REC_0017248 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.2 | 52 | female | 0 | 18 | 6.1 | 6 | entrectinib 600 mg daily | 12.7 | true | MSI-H | 2026-03-15T05:36:02.085904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574179 | REC_0017249 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 7.6 | 66 | male | 1 | 5 | 5.5 | 2 | pembrolizumab 200 mg q3w | 4.4 | true | MSS | 2026-03-15T05:36:02.086290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945716 | REC_0017250 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 11.4 | 49 | male | 0 | 16 | 4.5 | 5 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:36:02.086639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681779 | REC_0017251 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 14 | 5.6 | 66 | male | 1 | 31 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.5 | false | MSS | 2026-03-15T05:36:02.086989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283545 | REC_0017252 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 14.2 | 69 | female | 0 | 13 | 3.8 | 7 | osimertinib 80 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:36:02.087497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511509 | REC_0017253 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 16.6 | 66 | female | 1 | 20 | 5.5 | 3 | osimertinib 80 mg daily | 8.3 | false | MSS | 2026-03-15T05:36:02.087872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109438 | REC_0017254 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7 | 55 | male | 0 | 23 | 7.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:36:02.088312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429248 | REC_0017255 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 6.5 | 74 | female | 2 | 9 | 6 | 7 | sotorasib 960 mg daily | 13.4 | true | MSS | 2026-03-15T05:36:02.088700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641333 | REC_0017256 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 8.2 | 66 | female | 1 | 14 | 4.5 | 5 | osimertinib 80 mg daily | 9.6 | true | MSS | 2026-03-15T05:36:02.089039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593637 | REC_0017257 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 18.7 | 79 | female | 2 | 18 | 7.5 | 1 | osimertinib 80 mg daily | 15.3 | true | MSS | 2026-03-15T05:36:02.089367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654031 | REC_0017258 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 7.9 | 78 | female | 2 | 16 | 5 | 1 | osimertinib 80 mg daily | 20.1 | true | MSS | 2026-03-15T05:36:02.089695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720511 | REC_0017259 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 18 | 5.2 | 78 | female | 1 | 62 | 8 | 0 | carboplatin + paclitaxel + pembrolizumab | 24.6 | false | MSS | 2026-03-15T05:36:02.090016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860900 | REC_0017260 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 10.5 | 71 | male | 2 | 17 | 5.1 | 0 | entrectinib 600 mg daily | 8.3 | true | MSS | 2026-03-15T05:36:02.090346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934167 | REC_0017261 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 21.5 | 62 | female | 0 | 23 | 5.8 | 1 | osimertinib 80 mg daily | 17.1 | true | MSI-H | 2026-03-15T05:36:02.090661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221203 | REC_0017262 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.3 | 61 | female | 1 | 8 | 4.7 | 2 | osimertinib 80 mg daily | 22.9 | true | MSI-H | 2026-03-15T05:36:02.090978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570634 | REC_0017263 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14 | 63 | male | 0 | 13 | 4.6 | 6 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:36:02.091285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941743 | REC_0017264 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14 | 60 | female | 1 | 17 | 4.7 | 3 | osimertinib 80 mg daily | 15.2 | true | MSS | 2026-03-15T05:36:02.091614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293647 | REC_0017265 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11.2 | 71 | female | 2 | 20 | 3.9 | 1 | osimertinib 80 mg daily | 20.2 | false | MSS | 2026-03-15T05:36:02.092211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785051 | REC_0017266 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 26 | 14.2 | 61 | male | 1 | 18 | 2.6 | 0 | osimertinib 80 mg daily | 43.4 | true | MSS | 2026-03-15T05:36:02.092693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988308 | REC_0017267 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 7.5 | 68 | female | 1 | 10 | 6.5 | 9 | pembrolizumab 200 mg q3w | 12.6 | true | MSS | 2026-03-15T05:36:02.093121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201582 | REC_0017268 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 14.2 | 70 | female | 2 | 19 | 4.3 | 1 | alectinib 600 mg BID | 16.8 | false | MSS | 2026-03-15T05:36:02.097259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215595 | REC_0017269 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.3 | 63 | male | 1 | 18 | 4.6 | 5 | alectinib 600 mg BID | 10.9 | false | MSI-H | 2026-03-15T05:36:02.097683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113197 | REC_0017270 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6 | 71 | female | 0 | 55 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:36:02.098106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465157 | REC_0017271 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 2.6 | 65 | female | 1 | 0 | 7.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 5.5 | false | MSS | 2026-03-15T05:36:02.098550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661296 | REC_0017272 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 14.9 | 66 | female | 1 | 16 | 6.1 | 2 | entrectinib 600 mg daily | 24.5 | true | MSS | 2026-03-15T05:36:02.098950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739140 | REC_0017273 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 23.1 | 71 | female | 2 | 14 | 4.4 | 1 | osimertinib 80 mg daily | 22.4 | false | MSS | 2026-03-15T05:36:02.099299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140845 | REC_0017274 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.1 | 68 | female | 0 | 18 | 5.8 | 6 | alectinib 600 mg BID | 15.1 | true | MSI-H | 2026-03-15T05:36:02.099603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491779 | REC_0017275 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 6.4 | 62 | female | 1 | 18 | 5.3 | 2 | pembrolizumab 200 mg q3w | 23.5 | true | MSS | 2026-03-15T05:36:02.099926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268452 | REC_0017276 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 14.9 | 77 | female | 2 | 20 | 6.9 | 4 | alectinib 600 mg BID | 6.9 | true | MSI-H | 2026-03-15T05:36:02.100391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596968 | REC_0017277 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 12.6 | 74 | female | 2 | 12 | 8.6 | 2 | entrectinib 600 mg daily | 20.3 | true | MSS | 2026-03-15T05:36:02.100789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742820 | REC_0017278 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 9.2 | 70 | male | 1 | 0 | 5.4 | 1 | osimertinib 80 mg daily | 17.6 | false | MSS | 2026-03-15T05:36:02.101352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535528 | REC_0017279 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.1 | 60 | male | 1 | 16 | 7.8 | 6 | alectinib 600 mg BID | 8.1 | false | MSI-H | 2026-03-15T05:36:02.101777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961540 | REC_0017280 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 15.6 | 61 | female | 1 | 14 | 3.2 | 2 | entrectinib 600 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:36:02.102134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512439 | REC_0017281 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 8.9 | 62 | female | 0 | 15 | 4.8 | 6 | osimertinib 80 mg daily | 6.8 | false | MSS | 2026-03-15T05:36:02.102467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624809 | REC_0017282 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 15.7 | 83 | male | 2 | 14 | 6 | 6 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:36:02.102802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952037 | REC_0017283 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 14.9 | 78 | female | 1 | 9 | 5.1 | 1 | osimertinib 80 mg daily | 21.6 | true | MSI-H | 2026-03-15T05:36:02.103127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718411 | REC_0017284 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9.7 | 80 | female | 2 | 19 | 6.6 | 5 | osimertinib 80 mg daily | 5.3 | true | MSS | 2026-03-15T05:36:02.103448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214517 | REC_0017285 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 8.7 | 57 | male | 0 | 21 | 5.7 | 1 | alectinib 600 mg BID | 23.4 | true | MSS | 2026-03-15T05:36:02.103774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421904 | REC_0017286 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 11.2 | 69 | male | 0 | 14 | 5.5 | 0 | osimertinib 80 mg daily | 36.9 | true | MSI-H | 2026-03-15T05:36:02.104263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741697 | REC_0017287 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 8.1 | 72 | female | 2 | 8 | 5.6 | 5 | pembrolizumab 200 mg q3w | 13.1 | true | MSS | 2026-03-15T05:36:02.104669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858396 | REC_0017288 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 12.7 | 68 | female | 1 | 18 | 4.7 | 6 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:36:02.105017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190275 | REC_0017289 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 18.1 | 63 | female | 0 | 22 | 3.6 | 7 | entrectinib 600 mg daily | 5.7 | false | MSI-H | 2026-03-15T05:36:02.105367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413529 | REC_0017290 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 5.1 | 57 | male | 1 | 9 | 3.9 | 4 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:36:02.105684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908482 | REC_0017291 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 18.3 | 67 | female | 0 | 17 | 6.3 | 2 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:36:02.106139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284107 | REC_0017292 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 34 | 10.4 | 69 | female | 0 | 4 | 5.3 | 2 | alectinib 600 mg BID | 16.3 | false | MSS | 2026-03-15T05:36:02.106483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289636 | REC_0017293 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 17.9 | 54 | male | 0 | 23 | 7 | 1 | alectinib 600 mg BID | 15.8 | false | MSI-H | 2026-03-15T05:36:02.106783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323284 | REC_0017294 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 10.3 | 62 | male | 1 | 9 | 5.2 | 1 | alectinib 600 mg BID | 12 | false | MSI-H | 2026-03-15T05:36:02.107080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346748 | REC_0017295 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 4.6 | 71 | female | 2 | 8 | 4.8 | 1 | sotorasib 960 mg daily | 14 | false | MSS | 2026-03-15T05:36:02.107379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144059 | REC_0017296 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13.3 | 74 | male | 1 | 16 | 6.2 | 2 | entrectinib 600 mg daily | 19 | false | MSI-H | 2026-03-15T05:36:02.107696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158028 | REC_0017297 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 8.6 | 62 | male | 1 | 38 | 3.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.4 | false | MSS | 2026-03-15T05:36:02.107997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473763 | REC_0017298 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 31 | 8.8 | 67 | female | 0 | 19 | 6 | 0 | entrectinib 600 mg daily | 48.1 | true | MSS | 2026-03-15T05:36:02.108426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325270 | REC_0017299 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 17.7 | 73 | female | 1 | 9 | 7.5 | 1 | pembrolizumab 200 mg q3w | 13.6 | false | MSI-H | 2026-03-15T05:36:02.108825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819221 | REC_0017300 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 16.5 | 78 | female | 1 | 16 | 6 | 5 | sotorasib 960 mg daily | 6.7 | false | MSI-H | 2026-03-15T05:36:02.109183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.